Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?

Orson W. Moe, Makoto Kuro-O

Research output: Contribution to journalComment/debate

5 Scopus citations

Abstract

Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

Original languageEnglish (US)
Pages (from-to)1022-1023
Number of pages2
JournalKidney international
Volume85
Issue number5
DOIs
StatePublished - May 2014

    Fingerprint

ASJC Scopus subject areas

  • Nephrology

Cite this